Alector stock falls as the phase II INVOKE-2 study evaluating AL002 in slowing disease progression in early Alzheimer's disease fails to meet the primary goal.

US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced ...

On a routine basis in recent years, headlines about layoffs in the biopharma industry have surfaced as companies large and ...

Alector (NASDAQ:ALEC – Free Report) had its target price lowered by BTIG Research from $16.00 to $5.00 in a research note ...

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on ALEC stock, giving a Buy rating today.Don't Miss our Black ...

Fintel reports that on November 26, 2024, Morgan Stanley downgraded their outlook for Alector (NasdaqGS:ALEC) from ...

Investigational simufilam failed to reduce cognitive or functional decline in Alzheimer's disease patients in the ReThink-ALZ ...

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Alector (ALEC – Research Report), reducing the price target to $7.00.Don't ...

Alector shares are trading lower by 14.9% during Wednesday's session. The company announced the pricing of a $75 million public offering.

Stock futures edged lower on Tuesday as sentiment took a hit after President-elect Donald Trump said he would raise tariffs ...

Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is ...

Alector’s internal pipeline suffered a blow as the Phase II INVOKE-2 trial evaluating its Alzheimer’s disease therapy, AL002, ...